Detection of ovarian cancer specific gene mutation in uterine secretion using LiquidSCA

Not Applicable

• Conditions: Neoplasms

• Registration Number: KCT0007000
• Lead Sponsor: Chung-Ang Univerisity Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 8 March 2022

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Female
• Target Recruitment: 44

Inclusion Criteria

Normal group
1. A woman between the ages of 20 and 70 who came to the hospital for routine examination
2. A woman who has no abnormal findings in the endometrium or ovaries on ultrasound at the examination and normal PAP test within the last 2 years(if there is uterine fibroids or adenomyosis, it may be included in the this group)
Benign ovarian cyst group
1. Women between the ages of 20 and 70
2. A woman who has no abnormal findings in the endometrium or ovaries on ultrasound, and normal PAP test within the last 2 years. (if there is uterine fibroids or adenomyosis, it may be included in this group)
3. Imaging (US or MRI or CT), tumor marker level, or clinically not suspected ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
4. Patients whose ovaries or fallopian tubes are included in the surgical procedure.

Exclusion Criteria

1. Patients who have previously had bilateral salpingectomy
2. Patients who underwent tubal ligation for the purpose of contraception
3. Patients who have received chemotherapy, radiotherapy, biological treatment, or drugs in clinical trials after being diagnosed with ovarian cancer
4. Patients diagnosed with ovarian, fallopian, primary peritoneal cancer or metastasis of cancer to other organs in the final pathological examination.

Study & Design

• Study Type: Observational Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ovarian cancer specific gene mutation

Secondary Outcome Measures

Name	Time	Method
diagnostic performance of ovarian cancer specific gene